In 1991, in the week that the Food and Drug Administration held regulatory hearings on fluoxetine and suicide, the BMJ published an article by Lilly employees exonerating fluoxetine, although the article showed a clear increase in risk with treatment and included under the heading of placebo a suicide that had not happened in the randomised phase of the trials.1 2 This likely played a part in the way academics worldwide …